Form 4: Mirum Pharmaceuticals Director Increases Stake Through Stock and Option Acquisitions

William Fairey, a Director at Mirum Pharmaceuticals, Inc., has acquired additional common stock, stock options, and deferred stock units as part of compensation, increasing his beneficial ownership.

Summary

• William Fairey, a Director of Mirum Pharmaceuticals, Inc. (MIRM), reported changes in his beneficial ownership of company securities.
• On May 29, 2025, Mr. Fairey acquired 5,703 shares of common stock through the conversion of Restricted Stock Units (RSUs).
• He also acquired 6,268 stock options with an exercise price of $44 per share, expiring on May 28, 2035.
• Additionally, Mr. Fairey acquired 3,977 Deferred Stock Units (DSUs).
• The 5,703 Restricted Stock Units (RSUs) vest on the first anniversary of the grant date or, in any case, are fully vested on the date of the Issuer's 2025 annual stockholder meeting.
• The 6,268 stock options vest on the first anniversary of the grant date or, in any case, are fully vested on the date of the Issuer's 2026 annual stockholder meeting.
• The 3,977 Deferred Stock Units (DSUs) vest on the first anniversary of the grant date or, in any case, are fully vested on the date of the Issuer's 2026 annual stockholder meeting.
• Vested Deferred Stock Units will be paid out in common stock upon the earliest of a change in control of the Issuer or within 60 days following separation from service.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their stake in the company through compensation-related equity acquisitions, which generally signals confidence and aligns management interests with shareholders. This is a routine but positive disclosure.

Positives

• A director, William Fairey, has increased his beneficial ownership in Mirum Pharmaceuticals, Inc. through the acquisition of common stock, stock options, and deferred stock units.
• The acquisition of these securities aligns the director's interests more closely with those of the shareholders, indicating confidence in the company's future.
• The transactions are part of compensation, suggesting a structured approach to executive incentives.

Future Outlook

The vesting schedules for the acquired restricted stock units, stock options, and deferred stock units indicate future potential share acquisitions for the director, aligning long-term incentives with company performance.

Industry Context

Insider transactions, such as those reported in a Form 4, are common in the biotechnology and pharmaceutical industries as a form of executive and director compensation, aiming to align leadership interests with long-term shareholder value. These transactions reflect standard equity incentive practices.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a director can be viewed positively as it aligns management's interests with shareholder value creation.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and morale.

Next Steps

• Future vesting of the remaining Restricted Stock Units on the first anniversary of the grant date or by the 2025 annual stockholder meeting.
• Future vesting of the acquired Stock Options on the first anniversary of the grant date or by the 2026 annual stockholder meeting.
• Future vesting of the Deferred Stock Units on the first anniversary of the grant date or by the 2026 annual stockholder meeting.
• Potential exercise of stock options prior to their expiration on May 28, 2035.
• Payout of vested Deferred Stock Units upon a change in control or separation from service.

Key Dates

Recommendation

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Stock Options, Deferred Stock Units, Director Compensation, Equity Compensation